Relationship between Antigen Release and Antibody Response of Infectious Coryza Water-in-Oil-in-Water Emulsion Vaccines

Fukanoki, Shinichi; Matsumoto, Keīichi; Mori, Hajime; Takeda, Reiji

doi:10.2307/1593059

Cited by 7 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(Snippe et al, 1981; Shakya and Nandakumar, 2013), and RHEODOL AO-15V (sorbitan sesquioleate) (Fukanoki et al, 2000, 2001). Three of these five compounds (i.e., ethanol, gum arabic, and RHEODOL AO-15V) were used to prepare the nanoemulsion W805EC, the OW-14 emulsion, and a water-in-oil-in-water emulsion, respectively (Fukanoki et al, 2000, 2001; Das et al, 2012; Galliher-Beckley et al, 2015) and showed their adjuvant effects as part of these emulsions; however, the adjuvant effect of each compound per se has not previously been shown. To our knowledge, this is the first report to demonstrate their adjuvanticity outside of an emulsion formulation.…”

Section: Resultsmentioning

confidence: 99%

Injectable Excipients as Novel Influenza Vaccine Adjuvants

et al. 2019

View full text Add to dashboard Cite

Influenza outbreaks can be either seasonal or pandemic. Vaccination is an effective strategy to control influenza; however, the efficacy of the currently available inactivated influenza virus vaccines is suboptimal, especially in the elderly. Vaccine efficacy can be improved by the addition of adjuvants, but few adjuvants have been approved for human vaccines. To explore novel, safe, and effective adjuvants for influenza vaccines, here we used a mouse model to screen 46 injectable drug additives approved in Japan. Of these 46 candidates, we identified 20 compounds that enhanced the efficacy of the split influenza HA vaccine against lethal virus challenge. These 20 compounds included 15 novel adjuvant candidates and 5 compounds with previously reported adjuvant effects for other antigens but not for influenza vaccine. Given that these additives are already approved for human use, the hurdle for their clinical use as novel and effective adjuvants for influenza or other vaccines is lower than for other adjuvant candidates whose safety profiles are unknown.

show abstract

Section: Resultsmentioning

confidence: 99%

Injectable Excipients as Novel Influenza Vaccine Adjuvants

et al. 2019

View full text Add to dashboard Cite

show abstract

“…A double emulsion adjuvant (DEA) is a water-in-oil-in-water emulsion, and emulsions include water droplets surrounded within larger oil droplets, which are dispersed in an external water phase (Jansen et al, 2006). Antigens may be trapped within either the internal water droplets or the external water phase (Fukanoki et al, 2000). Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a member of the cytokines and is a biological adjuvant.…”

Section: Introductionmentioning

confidence: 99%

Development and evaluation of a recombinant VP2 neutralizing epitope antigen vaccine candidate for infectious bursal disease virus

Guo

Sun

Wei

et al. 2021

Transbound Emerg Dis

View full text Add to dashboard Cite

Infectious bursal disease (IBD) is one of the most economically important infectious diseases. Currently, vaccination is the most effective method to prevent IBD.Medium-virulence vaccines can damage the bursa of Fabricius and result in immunosuppression. Therefore, it is essential to develop a safe and effective vaccine against infectious bursal disease virus (IBDV). In this study, the five neutralizing epitopes of the IBDV VP2 protein were confirmed by neutralizing single chain variable fragment antibodies. Then, the neutralizing epitopes antigen (NEA) protein was constructed with five neutralizing epitopes and expressed by pET-27b. Furthermore, the immune effect and protective immunity of the NEA protein with the following adjuvants were evaluated in specific-pathogen-free chickens: oil emulsion adjuvant (OEA), double emulsion adjuvant (DEA), granulocyte-macrophage colony-stimulating factor (GM-CSF) adjuvant and complete Freund's adjuvant (CFA). The experimental results demonstrated that chickens immunized with NEA vaccines elicited stronger humoral and/ or cellular immune responses and inflammatory responses than those in the NEA protein group. Chickens were protected in OEA, CFA and GM-CSF adjuvant groups, which were challenged with virulent IBDV BC6/85. Furthermore, IBDV RNA was not measured, and there appeared to be little apoptosis in the bursa of Fabricius based on TUNEL histology and the expression of Bax and Bcl-2 in the OEA, CFA and GM-CSF adjuvant groups. Based on the experimental results, the advantages and disadvantages of adjuvants and industrial production methods, GM-CSF was found to be the optimal adjuvant. Therefore, NEA with GM-CSF adjuvant is a promising vaccine candidate against IBDV, and it provides a framework for developing other vaccines against infectious viral diseases.

show abstract